Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
natural killer cells
Biotech
AbbVie halts development of Dragonfly cancer asset in midflight
AbbVie has terminated a phase 1 trial of the natural killer-cell engager ABBV-303, licensed from Dragonfly as part of an ongoing partnership.
Darren Incorvaia
Oct 29, 2025 1:47pm
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Gilead's Kite erodes $2.3B Shoreline cell therapy deal
Sep 3, 2025 3:18pm
CEO invests own cash to move NKGen toward Alzheimer’s readout
May 8, 2025 10:22am
Innate antibody pits NK cells against lymphoma in animal models
Nov 15, 2024 2:00pm
MD Anderson launches cell therapy institute with $80M
Nov 11, 2024 4:20pm
